4.6 Review

Severe Asthma in Primary Care: Identification and Management

期刊

AMERICAN JOURNAL OF MEDICINE
卷 131, 期 5, 页码 484-491

出版社

ELSEVIER SCIENCE INC
DOI: 10.1016/j.amjmed.2017.12.034

关键词

Asthma; Biologic therapy; Biomarkers; Endotypes; Phenotypes; Severe; Uncontrolled

资金

  1. AstraZeneca (Wilmington, Del)

向作者/读者索取更多资源

Most patients with asthma are managed by primary care providers. Severe asthma is associated with substantial morbidity and health care resource use, and long-term sequelae of severe asthma include airway remodeling and a greater risk of developing chronic obstructive pulmonary disease. These consequences highlight the importance of early identification and improved management of patients with severe asthma. Although treatment guidelines can be confusing and it can be difficult to keep abreast of updates, routine assessments of lung function, frequency and severity of exacerbations, symptom control, and medication adherence in the primary care setting provide the necessary information for identifying severe asthma and determining appropriate management strategies. An increased understanding of asthma pathophysiology and its relationship to disease activity has identified therapeutic targets and associated biomarkers. Biologic therapies directed at these targets offer individualized targeted treatment of severe asthma. We review evidence-based guidelines for identification and management of severe asthma, clarify the relationship of asthma control and asthma severity, and provide an overview of new biologic therapies offering additional treatment options for patients with severe asthma. (C) 2018 The Authors. Published by Elsevier Inc.

作者

我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。

评论

主要评分

4.6
评分不足

次要评分

新颖性
-
重要性
-
科学严谨性
-
评价这篇论文

推荐

暂无数据
暂无数据